Celltech announced recently that they were moving ahead with Phase III studies of their drug CDP870 which targets TNF-alpha (much like Remicade does). We probably won't see the results of this until 2005 but a successful trial would certainly be good news for Crohn's patients. Remicade is currently the only drug approved by the US FDA in this area and as a result it tends to be very expensive. Another positive is that CDP870 is injected rather than applied via infusion like Remicade.
Read More...